Targeting strategies in cancer gene therapy

Acta Biochimica et Biophysica Sinica

Volumn 35, Issue 4, 2003, Pages 311-316

  Wang, Jin Hui ^a   Liu, Xin Yuan ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Cancer; Gene therapy; Targeting

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CARCINOEMBRYONIC ANTIGEN; CELL SURFACE RECEPTOR; COAT PROTEIN; COMPLEMENTARY RNA; CRE RECOMBINASE; CYTOSINE DEAMINASE; DNA; DRUG VEHICLE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FLUCYTOSINE; GANCICLOVIR; HEPARAN; INTEGRIN; LIGAND; LIPOSOME; NAKED DNA; NEU DIFFERENTIATION FACTOR; POLYLYSINE; PROTEIN; PROTEIN P53; RIBOZYME; THYMIDINE KINASE; TVA HERBETA 1 BRIDGE PROTEIN; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ADENOVIRUS; ADENOVIRUS VECTOR; ANTINEOPLASTIC ACTIVITY; BACTERIUM; BIFIDOBACTERIUM; CANCER CELL; CANCER GROWTH; CATALYSIS; CELL SPECIFICITY; CLOSTRIDIUM; CONJUGATION; CROSS LINKING; DNA MODIFICATION; ECOTROPIC VIRUS; ENZYME DEGRADATION; GENE DELETION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE INACTIVATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GERM LINE; HEAD TUMOR; HERPES SIMPLEX VIRUS; HYPOXIA; IMMUNE RESPONSE; INFECTION; MALIGNANT NEOPLASTIC DISEASE; NECK TUMOR; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN TARGETING; RECEPTOR BINDING; REGULATORY MECHANISM; REOVIRUS; RETROVIRUS VECTOR; RNA CLEAVAGE; SALMONELLA TYPHIMURIUM; SHORT SURVEY; SMOOTH MUSCLE FIBER; SYSTEMIC CIRCULATION; TARGET CELL; TARGET ORGAN; TISSUE INJURY; TRANSGENE; VASCULAR ENDOTHELIUM; VIRUS INFECTIVITY; VIRUS REPLICATION;

DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; CLOSTRIDIUM; REOVIRUS SP.; SALMONELLA TYPHIMURIUM; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0038109970     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (34)

1. Snitkovsky S, Young JA. Targeting retroviral vector infection to cells that express heregulin receptors using a TVA-heregulin bridge protein. Virology, 2002, 292(1): 150-155
2. Kashentseva EA, Seki T, Curiel DT, Dmitriev IP. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res, 2002, 62(2): 609-616
3. Kleeff J, Fukahi K, Lopez ME, Friess H, Buchler MW, Sosnowski BA, Korc M. Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther, 2002, 9(6): 522-532
4. Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, Li H et al. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther, 2001, 8(13): 969-976
5. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors. Crit Rev Oncol Hematol, 2001, 38(3): 177-192
6. Erlwein O, Wels W, Schnierle BS. Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin A translocation domain to target gene transfer to human cancer cells. Virology, 2002, 302(2): 333-341
7. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol, 1996, 14(11): 1570-1573
8. Dehari H, Ito Y, Nakamura T, Kobune M, Sasaki K, Yonekura N, Kohama G et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther, 2003, 10(1): 75-85
9. Von Seggern DJ, Chiu CY, Fleck SK, Stewart PL, Nemerow GR. A helper-independent adenovirus vector with E1, E3, and fiber deleted: Structure and infectivity of fiberless particles. J Virol, 1999, 73(2): 1601-1608
10. MacKrell AJ, Soong NW, Curtis CM, Anderson WF. Identification of a subdomain in the Moloney murine leukemia virus envelope protein involved in receptor binding. J Virol, 1996, 70(3): 1768-1774
11. Fielding AK, Chapel-Fernandes S, Chadwick MP, Bullough FJ, Cosset FL, Russell SJ. A hyperfusogenic Gibbon ape leukemia envelope glycoprotein: Targeting of a cytotoxic gene by ligand display. Hum Gene Ther, 2000, 11(6): 817-826
12. Peng KW, Vile RG, Cosset FL, Russell SJ. Selective transduction of protease-rich tumors by matrix-matalloproteinase-targeted retroviral vectors. Gene Ther, 1999, 6(9): 1552-1557
13. Peng KW, Morling FJ, Cosset FL, Russell SJ. Retroviral gene delivery system activatable by plasmin. Tumor Targeting, 1998, 3: 112-120
14. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 1996, 274(5286): 373-376
15. Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther, 2002, 9(11): 935-945
16. Zhang L, Akbulut H, Tang Y, Peng X, Pizzorno G, Sapi E, Manegold S et al. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma. Mol Ther, 2002, 6(3): 386-393
17. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther, 2002, 13(14): 1737-1750
18. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science, 1998, 282(5392): 1332-1334
19. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med, 2000, 6(7): 821-825
20. Greco O, Scott SD, Marples B, Dachs GU. Cancer gene therapy: 'Delivery, delivery, delivery'. Front Biosci, 2002, 7: d1516-524
21. Dachs GU, Coralli C, Hart SL, Tozer GM. Gene delivery to hypoxic cells in vitro. Br J cancer, 2000, 83(5): 662-667
22. Jenkins RG, Herrick SE, Meng QH, Kinnon C, Laurent GJ, McAnulty RJ, Hart SL. An integrin-targeted non-viral vector for pulmonary gene therapy. Gene Ther, 2000, 7(5): 393-400
23. Iyer M, Berenji M, Templeton NS, Gambhir SS. Noninvasive imaging of cationic lipid-mediated delivery of optical and PET reporter genes in living mice. Mol Ther, 2002, 6(4): 555-562
24. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther, 2002, 9(4): 291-296
25. Bermudes D, Low B, Pawelek J. Tumor-targeted Salmonella. Highly selective delivery vectors. Adv Exp Med Biol, 2000, 465: 57-63
26. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res, 1997, 57(20): 4537-4544
27. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther, 2001, 8(23): 1801-1807
28. Meyer RG, Kupper JH, Kandolf R, Rodemann HP. Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro. Eur J Biochem, 2002, 269(1): 337-346
29. Burcin MM, O Malley BW, Tsai SY. A regulatory system for target gene expression. Front Biosci, 1998, 3: c1-7
30. Kijima T, Osaki T, Nishino K, Kumagai T, Funakoshi T, Goto H, Tachibana I et al. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen- producing cancer. Cancer Res, 1999, 59(19): 4906-4911
31. Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics. Curr Cancer Drug Targets, 2001, 1(3): 177-196
32. Wright L, Kearney P. Current status of ribozymes as gene therapy agents for cancer. Cancer Invest, 2001, 19(5): 495-509
33. Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res, 2002, 62(19): 5463-5469
34. Barnett BG, Tillman BW, Curiel DT, Douglas JT. Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol Ther, 2002, 6(3): 377-385